Apellis Pharmaceuticals, Inc. Earnings Recaps
Q3 2025
Nov 1, 2025
Apellis Pharmaceuticals delivered a strong third quarter in 2025, highlighted by the FDA approval of EMPAVELI for C3 glomerulopathy, enhancing its market position with differentiated treatment options.
Key takeaways
- EMPAVELI's approval increases the addressable market by approximately 5,000 patients, positioning it as the only comprehensive treatment for multiple patient populations.
- Early feedback on EMPAVELI's launch has been overwhelmingly positive, with physicians emphasizing its efficacy and ease of use via a compact auto-injector.
- SYFOVRE continues to face slow adoption despite its proven clinical profile, prompting strategic marketing initiatives aimed at accelerating growth in the geographic atrophy market.